Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 9/20 | 0.41 |
| ▸ | PPARA | Q07869 | 8/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102038 | 0.89 | SMN1; SMN2 (0.51) | S1PR1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10102036 | 0.89 | NPC1 (0.50) | S1PR1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10101741 | 0.89 | S1PR1 (0.48) | S1PR1L3MBTL1GAAPOLBMAPT | |
| SCHEMBL10101735 | 0.88 | S1PR1 (0.50) | S1PR1L3MBTL1GAAPOLBMAPT | |
| SCHEMBL10102085 | 0.85 | NPC1 (0.64) | S1PR1L3MBTL1GAAPOLBMAPT | |
| SCHEMBL10102022 | 0.85 | HPGD (0.45) | S1PR1L3MBTL1GAAMAPTNPC1 | |
| SCHEMBL10106877 | 0.85 | GAA (0.46) | S1PR1L3MBTL1GAAPOLBMAPT | |
| SCHEMBL10101746 | 0.85 | S1PR1 (0.43) | S1PR1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10101740 | 0.85 | NPC1 (0.48) | L3MBTL1NPC1RAB9ASMN1; SMN2PPARG | |
| SCHEMBL10101733 | 0.85 | S1PR1 (0.60) | S1PR1L3MBTL1GAAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | S1PR1 909/4885L3MBTL1 4843/4885GAA 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.